Rossella De Cecio

Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Modern Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: From Residual Tumor Quantification to Spatial and AI-Based Biomarkers.

Modern Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: From Residual Tumor Quantification to Spatial and AI-Based Biomarkers.

Journal: Cancers

Published: February 24, 2026

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial.

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial.

Journal: ESMO open

Published: July 02, 2025

Human papillomavirus 16 E6 oncoprotein promotes up-regulation of RNA-binding protein Sam68 in head and neck cancer.

Human papillomavirus 16 E6 oncoprotein promotes up-regulation of RNA-binding protein Sam68 in head and neck cancer.

Journal: Frontiers in microbiology

Published: July 01, 2025

Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study.

Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study.

Journal: Clinical and translational medicine

Published: April 17, 2025

Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma.

Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma.

Journal: Cancers

Published: January 07, 2025

Rare Primitive Lung Adenocarcinoma in Larynx: A Case Report.

Rare Primitive Lung Adenocarcinoma in Larynx: A Case Report.

Journal: Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India

Published: July 15, 2024

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 23, 2023

Risk Management Activities in a Lung Cancer Multidisciplinary Team at a Comprehensive Cancer Center: Results of a Prospective Analysis.

Risk Management Activities in a Lung Cancer Multidisciplinary Team at a Comprehensive Cancer Center: Results of a Prospective Analysis.

Journal: JCO oncology practice

Published: November 16, 2022

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

Journal: The Lancet. Oncology

Published: November 07, 2022

Lurbinectedin in small cell lung cancer.

Lurbinectedin in small cell lung cancer.

Journal: Frontiers in oncology

Published: April 29, 2022

Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.

Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 12, 2022

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.

Journal: ESMO open

Published: March 23, 2022

Showing 1-12 of 44

Last Updated: 09/26/2026